基因检测公司NeoGenomics（股票代码：NEO）今日盘中股价大跌24.92%，引发市场广泛关注。这一暴跌主要源于公司公布的最新季度财报显示亏损扩大，远超市场预期。
根据NeoGenomics发布的财报，截至6月30日的季度内，公司录得净亏损4509万美元，每股亏损35美分。虽然调整后每股收益为3美分，与去年同期持平，且略高于分析师平均预期的2美分，但巨额亏损仍令投资者感到失望。营收方面，公司实现1.8133亿美元，同比增长10.2%，但略低于分析师预期的1.8269亿美元。
值得注意的是，NeoGenomics的股价表现一直不佳。公司股价在过去一个季度已下跌11.6%，今年迄今为止更是累计下跌了60.8%。尽管分析师对公司保持相对乐观态度，平均评级为"买入"，并给出12美元的目标价，但过去三个月内，分析师的平均盈利预期下降了约30.7%。这些因素综合导致投资者对公司未来增长前景产生担忧，从而引发了今日的大幅抛售。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.